Drug therapy of advanced non-small cell lung cancer in the elderly.
10.3881/j.issn.1000-503X.2010.04.025
- Author:
Bin AI
1
;
Gang CHENG
Author Information
1. Department of Medical Oncology, Beijing Hospital, Beijing 100730, China. abincd2002@yahoo.com.cn
- Publication Type:Journal Article
- MeSH:
Aged;
Antibodies, Monoclonal;
therapeutic use;
Antineoplastic Agents;
therapeutic use;
Carcinoma, Non-Small-Cell Lung;
drug therapy;
Humans;
Lung Neoplasms;
drug therapy;
Receptor, Epidermal Growth Factor;
antagonists & inhibitors
- From:
Acta Academiae Medicinae Sinicae
2010;32(4):473-476
- CountryChina
- Language:Chinese
-
Abstract:
About half of the elderly patients with advanced non-small cell lung cancer (NSCLC) can not receive effective treatment due to the decreased organ function and complication. Monotherapies using the third generation new drugs have became a standard first-line therapy for NSCLC, as documented by prospective phase 3 clinical trials. Combined chemotherapies that contain platin and single agent are considered optional first- and second-line treatment for patients with good physical performance and few complication. The epidermal growth factor receptor tyrosine kinase inhibitors may become a key therapeutic agent,while the role of anti-vascular endothelial growth factor monoclonal antibody remains unclear. More prospective phase 3 targeting at the elderly patients should be designed and conducted.
